^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    davamotecan pegadexamer (EP0057)

    i
    Other names: EP0057, CRLX101, CRLX 101, IT-101, Cyclosert-enhanced camptothecin, NLG207, IT 101, nanoparticle-drug conjugate with camptothecin, CRLX-101, EP-0057, EP 0057, IT101, NLG-207, NLG 207
    Associations
    News

    Trials

    Company:
    Ellipses Pharma, Lumos Pharma
    Drug class:
    Topoisomerase I inhibitor, HIF-1α inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    EP0057 in Combination With Olaparib in Advanced Ovarian Cancer (NCT04669002)
    Phase 2
    Ellipses Pharma
    Completed
    Last update posted :
    08/02/2023
    Initiation :
    12/14/2020
    Primary completion :
    02/17/2023
    Completion :
    05/05/2023
    HRD • BRCA
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • irinotecan • davamotecan pegadexamer (EP0057)
    EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer (NCT05411679)
    Phase 2
    Ellipses Pharma
    Withdrawn
    Last update posted :
    06/12/2023
    Initiation :
    04/01/2023
    Primary completion :
    08/01/2024
    Completion :
    12/01/2024
    PD-L1 • ATM
    |
    ATM expression
    |
    Lynparza (olaparib) • davamotecan pegadexamer (EP0057)
    CRLX101 Plus Bevacizumab in Advanced RCC (NCT01625936)
    Phase 1b
    Abramson Cancer Center of the University of Pen...
    Completed
    Last update posted :
    08/29/2018
    Initiation :
    06/01/2012
    Primary completion :
    07/01/2017
    Completion :
    07/16/2018
    IL2
    |
    Avastin (bevacizumab) • davamotecan pegadexamer (EP0057)